Literature DB >> 19021617

Evidence for durable kidney stone prevention over several decades.

Joan H Parks1, Fredric L Coe.   

Abstract

OBJECTIVE: To analyse three outcomes of stone prevention strategies in one clinic devoted to that activity since 1969, i.e. stone recurrence rates, stone-related procedures and 24-h urinary stone risk factor, to assess whether such treatment can be maintained over long periods. PATIENTS AND METHODS: We selected 2509 patients with at least one laboratory follow-up after initial clinical and laboratory evaluation. We divided them into five time cohorts of 5, 10, 15, 20 and >20 years of follow-up. Rates of new stones and stone-related procedures, and 24-h urinary stone risk factors were compared between the cohorts using analysis of variance and general linear modelling.
RESULTS: Stone rates and rates of stone-related procedures declined in all five cohorts, as did 24-h urinary stone risk indices. We found no diminution of treatment effects for any of these three over time.
CONCLUSION: Those patients who remained under active care had significant reductions in stone recurrence and rates of stone-related urological procedures for up to >20 years. However, only a small fraction of patients who entered the clinic remained for such long periods. Urine testing substantiates impressive and sustained reductions in supersaturation, the principle driving force for stone formation. Overall, for those patients willing to remain in continuous treatment for periods of up to three decades, medical stone prevention appears to be effective in maintaining low recurrence and procedure rates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19021617      PMCID: PMC2768493          DOI: 10.1111/j.1464-410X.2008.08170.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  21 in total

Review 1.  Kidney stones.

Authors:  D A Bushinsky
Journal:  Adv Intern Med       Date:  2001

Review 2.  Evaluation of the recurrent stone former.

Authors:  Paramjit S Chandhoke
Journal:  Urol Clin North Am       Date:  2007-08       Impact factor: 2.241

Review 3.  Medical therapy, calcium oxalate urolithiasis.

Authors:  L A Ruml; M S Pearle; C Y Pak
Journal:  Urol Clin North Am       Date:  1997-02       Impact factor: 2.241

4.  Urine stone risk factors in nephrolithiasis patients with and without bowel disease.

Authors:  Joan H Parks; Elaine M Worcester; R Corey O'Connor; Fredric L Coe
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

5.  Patient adherence to long-term medical treatment of kidney stones.

Authors:  J H Parks; J R Asplin; F L Coe
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

6.  Thiazide prophylaxis of urolithiasis. A double-blind study in general practice.

Authors:  E Laerum; S Larsen
Journal:  Acta Med Scand       Date:  1984

7.  Randomized trial of allopurinol in the prevention of calcium oxalate calculi.

Authors:  B Ettinger; A Tang; J T Citron; B Livermore; T Williams
Journal:  N Engl J Med       Date:  1986-11-27       Impact factor: 91.245

8.  Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences.

Authors:  L Borghi; T Meschi; A Guerra; A Novarini
Journal:  J Cardiovasc Pharmacol       Date:  1993       Impact factor: 3.105

9.  Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis.

Authors:  P Barcelo; O Wuhl; E Servitge; A Rousaud; C Y Pak
Journal:  J Urol       Date:  1993-12       Impact factor: 7.450

10.  Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not.

Authors:  B Ettinger; J T Citron; B Livermore; L I Dolman
Journal:  J Urol       Date:  1988-04       Impact factor: 7.450

View more
  15 in total

Review 1.  Pharmacotherapy of urolithiasis: evidence from clinical trials.

Authors:  Orson W Moe; Margaret S Pearle; Khashayar Sakhaee
Journal:  Kidney Int       Date:  2010-10-06       Impact factor: 10.612

2.  Arguments for a comprehensive metabolic evaluation of the first-time stone former.

Authors:  Ryan F Paterson
Journal:  Can Urol Assoc J       Date:  2010-06       Impact factor: 1.862

Review 3.  Metabolic risk-evaluation and prevention of recurrence in stone disease: does it make sense?

Authors:  Hans-Göran Tiselius
Journal:  Urolithiasis       Date:  2015-11-27       Impact factor: 3.436

4.  Update on the evaluation of repeated stone formers.

Authors:  Adam O Kadlec; Thomas M Turk
Journal:  Curr Urol Rep       Date:  2013-12       Impact factor: 3.092

5.  Feasibility of a Telemedicine-Administered, Pharmacist-Staffed, Protocol-Driven, Multicenter Program for Kidney Stone Prevention in a Large Integrated Health Care System: Results of a Pilot Program.

Authors:  Mark E Gasparini; Toby W Chang; Mark St Lezin; John E Skerry; Andy Chan; Krishna A Ramaswamy
Journal:  Perm J       Date:  2019-11-01

Review 6.  Clinical practice. Calcium kidney stones.

Authors:  Elaine M Worcester; Fredric L Coe
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

Review 7.  Effectiveness of Treatment Modalities on Kidney Stone Recurrence.

Authors:  Anna L Zisman
Journal:  Clin J Am Soc Nephrol       Date:  2017-08-22       Impact factor: 8.237

Review 8.  Pathophysiology-based treatment of idiopathic calcium kidney stones.

Authors:  Fredric L Coe; Andrew Evan; Elaine Worcester
Journal:  Clin J Am Soc Nephrol       Date:  2011-08       Impact factor: 8.237

9.  Metabolic evaluation guidelines in patients with nephrolithiasis: Are they being followed? Results of a national, multi-institutional, quality-assessment study.

Authors:  Sabrina S Harmouch; Hiba Abou-Haidar; Hassan Elhawary; Thomas Grgic; Andrea G Lantz; Jason Y Lee; Ben H Chew; Sero Andonian; Naeem Bhojani
Journal:  Can Urol Assoc J       Date:  2018-05-28       Impact factor: 1.862

10.  Rationale and Design of the Registry for Stones of the Kidney and Ureter (ReSKU): A Prospective Observational Registry to Study the Natural History of Urolithiasis Patients.

Authors:  Helena C Chang; David T Tzou; Manint Usawachintachit; Brian D Duty; Ryan S Hsi; Jonathan D Harper; Mathew D Sorensen; Marshall L Stoller; Roger L Sur; Thomas Chi
Journal:  J Endourol       Date:  2016-11-01       Impact factor: 2.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.